The upcoming 18th annual CTAD conference (CTAD25) will take place in San Diego, USA, from December 1-4, 2025. CTAD25 is poised to build on the momentum of previous years, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today.
At the recently concluded CTAD24 in Madrid, Spain, over 2,500 international leaders convened to discuss groundbreaking developments in AD clinical research. Highlights from 2024 included:
- The one-year experience of recently marketed anti-amyloid treatments.
- Integration of blood biomarkers into clinical practice and trials.
- Promising results from Phase 1 and Phase 2 AD clinical trials.
